†Present address: Centre for Infectious Disease Research, Diagnostics and Screening (IDS), Centre for infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands.
Pleconaril is a capsid inhibitor used previously to treat enterovirus infections. A pleconaril-resistant echovirus 11 (E11) strain was identified before pleconaril treatment was given in an immunocompromised patient. The patient was also treated with intravenous Ig (IVIg) for a long period but remained unresponsive. The pleconaril-resistant strains could not be neutralized in vitro, confirming IVIg treatment failure. To identify the basis of pleconaril resistance, genetic and structural analyses were conducted. Analysis of a modelled viral capsid indicated conformational changes in the hydrophobic pocket that could prevent pleconaril docking. Substitutions (V117I, V119M and I188L) in the pleconaril-resistant viruses were found in the pocket region of VP1. Modelling suggested that V119M could confer resistance, most probably due to the protruding sulfate side chain of methionine. Although pleconaril resistance induced in vitro in a susceptible E11 clinical isolate was characterized by a different substitution (I183M), resistance was suggested to also result from a similar mechanism, i.e. due to a protruding sulfate side chain of methionine. Our results showed that resistant strains that arise in vivo display different markers from those identified in vitro and suggest that multiple factors may play a role in pleconaril resistance in patient strains. Based on IVIg treatment failure, we predict that one of these factors could be immune related. Thus, both IVIg and capsid inhibitors target the viral capsid and can induce mutations that can be cross-reactive, enabling escape from both IVIg and the drug. This could limit treatment options and should be investigated further.
BenschopK., MolenkampR., van der HamA., WolthersK., BeldM.2008a; Rapid detection of human parechoviruses in clinical samples by real-time PCR. J Clin Virol 41:69–74 [View Article][PubMed]
BenschopK., ThomasX., SerpentiC., MolenkampR., WolthersK.2008b; High prevalence of human parechovirus (HPeV) genotypes in the Amsterdam region and identification of specific HPeV variants by direct genotyping of stool samples. J Clin Microbiol 46:3965–3970 [View Article][PubMed]
BenschopK., MinnaarR., KoenG., van EijkH., DijkmanK., WesterhuisB., MolenkampR., WolthersK.2010; Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping. Diagn Microbiol Infect Dis 68:166–173 [View Article][PubMed]
HanL. Y., LinH. H., LiZ. R., ZhengC. J., CaoZ. W., XieB., ChenY. Z.2006; pearls: program for energetic analysis of receptor-ligand system. J Chem Inf Model 46:445–450 [View Article][PubMed]
HaydenF. G., HerringtonD. T., CoatsT. L., KimK., CooperE. C., VillanoS. A., LiuS., HudsonS., PevearD. C.other authors2003; Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 36:1523–1532 [View Article][PubMed]
HeinzB. A., RueckertR. R., ShepardD. A., DutkoF. J., McKinlayM. A., FancherM., RossmannM. G., BadgerJ., SmithT. J.1989; Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol 63:2476–2485[PubMed]
KronemanA., VennemaH., DeforcheK., AvoortH. v. d., PeñarandaS., ObersteM. S., VinjéJ., KoopmansM.2011; An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol 51:121–125 [View Article][PubMed]
LaskowskiR. A., WatsonJ. D., ThorntonJ. M.2005; ProFunc: a server for predicting protein function from 3D structure. Nucleic Acids Res 33:Web Server issueW89–W93 [View Article][PubMed]
LaurieA. T., JacksonR. M.2005; Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21:1908–1916 [View Article][PubMed]
LedfordR. M., PatelN. R., DemenczukT. M., WatanyarA., HerbertzT., CollettM. S., PevearD. C.2004; VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol 78:3663–3674 [View Article][PubMed]
LedfordR. M., CollettM. S., PevearD. C.2005; Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril. Antiviral Res 68:135–138 [View Article][PubMed]
McWilliam LeitchE. C., HarvalaH., RobertsonI., UbillosI., TempletonK., SimmondsP.2009; Direct identification of human enterovirus serotypes in cerebrospinal fluid by amplification and sequencing of the VP1 region. J Clin Virol 44:119–124 [View Article][PubMed]
PettersenE. F., GoddardT. D., HuangC. C., CouchG. S., GreenblattD. M., MengE. C., FerrinT. E.2004; UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612 [View Article][PubMed]
PevearD. C., FancherM. J., FelockP. J., RossmannM. G., MillerM. S., DianaG., TreasurywalaA. M., McKinlayM. A., DutkoF. J.1989; Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol 63:2002–2007[PubMed]
PevearD. C., HaydenF. G., DemenczukT. M., BaroneL. R., McKinlayM. A., CollettM. S.2005; Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 49:4492–4499 [View Article][PubMed]
Schneidman-DuhovnyD., InbarY., NussinovR., WolfsonH. J.2005; PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 33:Web Server issueW363–W367 [View Article][PubMed]
ShiaK. S., LiW. T., ChangC. M., HsuM. C., ChernJ. H., LeongM. K., TsengS. N., LeeC. C., LeeY. C.other authors2002; Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem 45:1644–1655 [View Article][PubMed]
StuartA. D., McKeeT. A., WilliamsP. A., HarleyC., ShenS., StuartD. I., BrownT. D., LeaS. M.2002; Determination of the structure of a decay accelerating factor-binding clinical isolate of echovirus 11 allows mapping of mutants with altered receptor requirements for infection. J Virol 76:7694–7704 [View Article][PubMed]